A Randomized Phase 3 Study, Sinus-52, Evaluating the Efficacy and Safety of Dupilumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps

We report results from a phase 3 dupilumab study (SINUS-52;NCT02898454) in severe CRSwNP patients on daily intranasal mometasone furoate (MFNS).

Source: Journal of Allergy and Clinical Immunology - February 1, 2019 Category: Allergy & Immunology Authors: Claus Bachert, Martin Desrosiers, Joaquim Mullol, Peter W. Hellings, Anders Cervin, Lawrence Sher, John V. Bosso, Stella E. Lee, Jorge F. Maspero, Shigeharu Fujieda, Shoji Matsune, Xin Lu, Chunpeng Fan, Steven Draikiwicz, Nikhil Amin, Siddhesh Kamat, Asif Source Type: research